CSIR has launched BGR-34, an anti-diabetic ayurvedic drug designed for type 2 Diabetes mellitus

Council for Scientific and Industrial Research (CSIR) on 27th June launched BGR-34 - an anti-diabetic ayurvedic drug designed for type 2 Diabetes mellitus.
•    BGR-34 is developed jointly by National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP), the research units of CSIR at Lucknow.
•    BGR-34 has been economically priced at Rs. 5 per tablet as compared to latest DPP4 inhibitors globally, a joint release by NBRI and CIMAP and the manufacturer AIMIL Pharmaceuticals (India) Ltd, said.
•    A K S Rawat, Sr Principal Scientist of CSIR-NBRI said six crore of the adult Indian population had been found to be diabetic and there is no effective solution for diabetes as yet.
•    He said CSIR's premier research institutions have developed and established the efficacy of BGR-34.
•    The modern diabetes drugs are known for side-effects and toxicity while BGR-34 works by controlling blood sugar and limiting the harmful effects of other drugs, he added.
•    The scientists of NBRI and CIMAP joined hands in developing the drug and they had in-depth study of over 500 renowned ancient herbs and finally identified the six best herbs listed in Ayurvedic ancient texts to develop an anti-diabetic formulation.